June 2015
Volume 56, Issue 7
Free
ARVO Annual Meeting Abstract  |   June 2015
Comparing Total and Disease Related Healthcare Cost of Glaucoma Patients by Disease Severity: A Retrospective Claims Database Analysis.
Author Affiliations & Notes
  • Tracy Yep
    US Health Outcomes, Allergan, Inc, Santa Ana, CA
    Pharmaceutical Outcomes Research and Policy Program (PORPP), University of Washington, Seattle, WA
  • Vaishali D Patel
    US Health Outcomes, Allergan, Inc, Santa Ana, CA
  • Julia Slejko
    Pharmaceutical Health Services Research, University of Maryland School of Pharmacy, Baltimore, MD
  • Beth Devine
    Pharmaceutical Outcomes Research and Policy Program (PORPP), University of Washington, Seattle, WA
  • Footnotes
    Commercial Relationships Tracy Yep, Allergan, Inc (F); Vaishali Patel, Allergan, Inc (E); Julia Slejko, None; Beth Devine, None
  • Footnotes
    Support None
Investigative Ophthalmology & Visual Science June 2015, Vol.56, 2129. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to Subscribers Only
      Sign In or Create an Account ×
    • Get Citation

      Tracy Yep, Vaishali D Patel, Julia Slejko, Beth Devine; Comparing Total and Disease Related Healthcare Cost of Glaucoma Patients by Disease Severity: A Retrospective Claims Database Analysis.. Invest. Ophthalmol. Vis. Sci. 2015;56(7 ):2129.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose: Little is known about the relationship between glaucoma severity and cost. Few studies characterize healthcare costs in glaucoma patients, and none have characterized glaucoma related costs by disease severity. In this study we performed a retrospective database analysis to characterize the total healthcare costs and disease related costs for open-angle glaucoma patients, using ICD-9 disease severity categories.

Methods: We analyzed a large US commercial claims database to identify patients 18 years and older with glaucoma occurring in 2011. Inclusion criteria included: two separate occurrences of any combination of open-angle glaucoma (ICD-9 codes 365.10 or 365.11); and presence of a glaucoma severity code in the 12 months after first diagnosis (ICD-9 codes: 365.71, 365.72, 365.73). Patients were excluded for presence of a glaucoma code in the 12 months before first diagnosis. Outcomes of interest were the total healthcare and glaucoma specific costs by disease severity for 12-months post-diagnosis. Generalized linear modeling (GLM) with adjustment for clinically relevant baseline characteristics was used to estimate the mean costs of the mild, moderate, and severe glaucoma categories for both total healthcare and glaucoma specific costs.

Results: 899 open-angle glaucoma patients were identified in 2011 who also had an ICD-9 glaucoma severity code (mild n= 542; moderate n= 271; severe n= 86). Glaucoma specific multivariable adjusted GLM results produced mean costs of: $470 (95% CI: $433, $508; p ≤0.001) for mild category, $625 (95% CI: $546, $703; p ≤0.001) for moderate category and $1,037 (95% CI: $781, $1,293; p ≤0.001) for severe glaucoma category. The multivariable adjusted mean total healthcare costs were $5,161 ($4,278, $6,043; p ≤0.001) for mild severity, $5,206 (95% CI: $4,151, $6,261; p ≤0.001) for moderate severity and $10,348 (95% CI: $5,144, $15,552; p ≤0.001) for severe glaucoma severity.

Conclusions: This study demonstrates that glaucoma specific costs and total healthcare costs increase with increasing severity of glaucoma amongst commercially insured patients.

×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×